-
1.发明授权SULFONYLAMINO-CARBONSÄURE-N-ARYLAMIDE ALS GUANYLATCYCLASE-AKTIVATOREN 有权磺酰胺亚胺基亚胺酰胺ALS GUANYLATCYCLASE-AKTIVATOREN
公开(公告)号：EP1095015B1
公开(公告)日：2005-06-01
申请号：EP99936460.7
申请日：1999-06-25
IPC分类号： C07C311/21
CPC分类号： C07F9/4056 , C07C311/21 , C07D207/27 , C07D207/325 , C07D207/404 , C07D209/08 , C07D209/48 , C07D215/48 , C07D217/02 , C07D217/24 , C07D231/56 , C07D235/18 , C07D241/20 , C07D249/18 , C07D295/135 , C07D295/192 , C07D307/91 , C07D311/16 , C07D317/60 , C07D409/04 , C07F9/3882
摘要： The invention relates to compounds of formula (I), wherein A?1, A2, R2 and R3¿ have the meanings cited in the claims. Said compounds are valuable pharmaceutical active substances for the treatment and prophylaxis of diseases, e.g. cardiovascular diseases such a hypertension, angina pectoris, heart failures, thrombosis or atherosclerosis. The compounds of formula (I) have the ability of modulating endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for treatment and prophylaxis of pathological states associated with cGMP metabolic disorders. The invention also relates to the use of compounds of formula (I) for treatment and prophylaxis of the above-mentioned pathological states and for producing corresponding medicaments, to pharmaceutical preparations containing said compounds and to a method of production.
摘要翻译： 本发明涉及式Ⅰ化合物，其中A 1，A 2，R 2和R 3具有权利要求中所示的含义，它们是用于治疗和预防的有价值的药物活性化合物 的疾病，例如心血管疾病如高血压，心绞痛，心功能不全，血栓形成或动脉粥样硬化。 式I的化合物具有调节环鸟苷酸（cGMP）的内源性产生的能力，并且通常适用于治疗和预防与扰动的cGMP平衡相关的疾病状态。 本发明涉及式I化合物用于治疗和预防指定疾病状态及其制备药物的用途，式I化合物，包含它们的药物制剂及其制备方法。
-
2.发明公开SUBSTITUIERTE 4-AMINO-2-ARYL-CYCLOPENTA D]PYRIMIDINE, IHRE HERSTELLUNG, IHRE VERWENDUNG UND SIE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE 有权取代的4-氨基-2-芳基 - 环戊并[d]嘧啶类，生产，使用和药物制剂含有它们
公开(公告)号：EP1131302A1
公开(公告)日：2001-09-12
申请号：EP99972626.8
申请日：1999-11-03
IPC分类号： C07D239/70 , C07D401/12 , A61K31/517
CPC分类号： C07D401/12 , C07D239/70
摘要： The present invention relates to compounds of formula (I) wherein R?1, R2 and R3¿ have the meanings given in the claims. Said compounds are valuable active agents in medicaments for the treatment and prophylaxis of diseases, for example cardiovascular diseases such as hypertension, angina pectoris, heart failure, thrombosis and atherosclerosis. The compounds of formula (I) are able to modulate the body's own production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the treatment and prophylaxis ofisorders associated with an impaired cGMP balance. The invention also relates to methods for producing compounds of formula (I), to their use in the treatment and prophylaxis of the above diseases and in the preparation of medicaments for such diseases, and to pharmaceutical preparations containing the compounds of formula (I).
-
3.发明授权SUBSTITUIERTE ISOINDOLONE UND IHRE VERWENDUNG ALS CYCLISCHE GMP MODULATOREN IN ARZNEIMITTELN 有权取代的异吲哚酮及其作为cGMP的调节剂药品
公开(公告)号：EP1064262B1
公开(公告)日：2003-02-12
申请号：EP99907548.4
申请日：1999-02-12
IPC分类号： C07D209/48 , A61K31/40 , C07D401/04 , C07D409/04
CPC分类号： C07D209/48 , C07D401/04 , C07D409/04
摘要： The invention relates to substituted isoindolon derivatives of formula (I), wherein R?1, R2, R3, R4, R5, R6 and R7¿ have the meanings cited in the description. Said derivatives represent valuable active substances in medicaments for the therapy and prophylaxis of diseases, e.g. cardiovascular diseases such a hypertension, angina pectoris, heart failures, thrombosis or atherosclerosis. The compounds of formula (I) are capable of modulating endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of pathological states associated with disorders of the cGMP metabolism. The invention also relates to a method for the production of compounds of formula (I), their use in the therapy and prophylaxis of the above-mentioned pathological states and in the production of medicaments for such states. The invention further relates to pharmaceutical preparations containing the compounds of formula (I).
-
4.发明公开SUBSTITUIERTE 2-ARYL-4-AMINO-CHINAZOLINE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS ARZNEIMITTEL 有权取代的2-芳基-4-氨基喹唑啉，生产和使用AS药物的方法
公开(公告)号：EP1040101A1
公开(公告)日：2000-10-04
申请号：EP98966301.8
申请日：1998-12-11
IPC分类号： C07D239/94 , A61K31/505
CPC分类号： C07D231/12 , C07D233/56 , C07D239/94 , C07D249/08 , C07D401/12 , C07D403/12
摘要： The invention relates to inventive compounds of formula (I), wherein R?1, R2, R3¿ and Ar have the meanings cited in the claims. The inventive compounds are suitable for use in the production of medicaments, e.g. for prophylaxis and therapy of cardiovasular diseases such as hypertension, angina pectoris, heart failure, thromboses or arteriosclerosis. The compounds of formula (I) have a capacity for modulating endogenic production of cyclic guanosine monophosphate (cGMP) and are generally suitable for therapy and prophylaxis of pathological conditions linked to cGMP metabolism disorders.
-
5.发明授权SUBSTITUTED 4-AMINO-2-ARYLTETRAHYDROQUINAZOLINES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM 有权取代的4-氨基-2- ARYLTETRAHYDROCHINAZOLINE，生产，其使用含药物组合物
公开(公告)号：EP1150963B1
公开(公告)日：2003-12-03
申请号：EP00901586.8
申请日：2000-01-22
IPC分类号： C07D239/94 , A61K31/505 , A61P9/00
CPC分类号： C07D239/94
-
6.发明授权SUBSTITUIERTE 4-AMINO-2-ARYL-PYRIMIDINE, IHRE HERSTELLUNG, IHRE VERWENDUNG UND SIE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE 有权取代的4-氨基-2-芳基 - 嘧啶，生产，使用和药物制剂含有它们
公开(公告)号：EP1112266B1
公开(公告)日：2003-05-14
申请号：EP99944330.2
申请日：1999-08-04
IPC分类号： C07D401/12 , C07D401/04 , C07D403/04 , C07D417/04 , C07D403/12 , A61K31/505 , A61K31/506 , A61P9/10 , A61P13/12 , A61P11/00
CPC分类号： C07D239/30 , C07D231/12 , C07D233/56 , C07D239/36 , C07D239/42 , C07D249/08 , C07D401/04 , C07D401/12 , C07D403/12 , C07D409/04 , C07D417/04
-
7.发明公开SUBSTITUIERTE 4-AMINO-2-ARYL-PYRIMIDINE, IHRE HERSTELLUNG, IHRE VERWENDUNG UND SIE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE 有权取代的4-氨基-2-芳基 - 嘧啶，生产，使用和药物制剂含有它们
公开(公告)号：EP1112266A1
公开(公告)日：2001-07-04
申请号：EP99944330.2
申请日：1999-08-04
IPC分类号： C07D401/12 , C07D401/04 , C07D403/04 , C07D417/04 , C07D403/12 , A61K31/505 , A61K31/506 , A61P9/10 , A61P13/12 , A61P11/00
CPC分类号： C07D239/30 , C07D231/12 , C07D233/56 , C07D239/36 , C07D239/42 , C07D249/08 , C07D401/04 , C07D401/12 , C07D403/12 , C07D409/04 , C07D417/04
摘要： The invention relates to compounds of formula (I) in which R?1, R2, R3 and R4¿ have the meanings given in the claims. Said compounds are valuable active ingredients for the treatment and prophylaxis of diseases, for example cardiovascular diseases such as hypertension, angina pectoris, heart failure, thrombosis and atherosclerosis. The compounds of formula (I) are able to modulate the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the treatment and prophylaxis of disorders associated with impaired cGMP balance. The invention further relates to methods for producing compounds of formula (I), their use in the treatment and prophylaxis of the above diseases and in the preparation of medicaments for such diseases, and to pharmaceutical preparations containing the compounds of formula (I).
-
8.发明公开
公开(公告)号：EP1095015A2
公开(公告)日：2001-05-02
申请号：EP99936460.7
申请日：1999-06-25
IPC分类号： C07C311/21
CPC分类号： C07F9/4056 , C07C311/21 , C07D207/27 , C07D207/325 , C07D207/404 , C07D209/08 , C07D209/48 , C07D215/48 , C07D217/02 , C07D217/24 , C07D231/56 , C07D235/18 , C07D241/20 , C07D249/18 , C07D295/135 , C07D295/192 , C07D307/91 , C07D311/16 , C07D317/60 , C07D409/04 , C07F9/3882
摘要： The invention relates to compounds of formula (I), wherein A?1, A2, R2 and R3¿ have the meanings cited in the claims. Said compounds are valuable pharmaceutical active substances for the treatment and prophylaxis of diseases, e.g. cardiovascular diseases such a hypertension, angina pectoris, heart failures, thrombosis or atherosclerosis. The compounds of formula (I) have the ability of modulating endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for treatment and prophylaxis of pathological states associated with cGMP metabolic disorders. The invention also relates to the use of compounds of formula (I) for treatment and prophylaxis of the above-mentioned pathological states and for producing corresponding medicaments, to pharmaceutical preparations containing said compounds and to a method of production.
-
9.发明公开SUBSTITUTED 4-AMINO-2-ARYLTETRAHYDROQUINAZOLINES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM 有权取代的4-氨基-2- ARYLTETRAHYDROCHINAZOLINE，生产，其使用含药物组合物
公开(公告)号：EP1150963A1
公开(公告)日：2001-11-07
申请号：EP00901586.8
申请日：2000-01-22
IPC分类号： C07D239/94 , A61K31/505 , A61P9/00
CPC分类号： C07D239/94
摘要： The present invention relates to compounds of formula (I) in which R?1, R2, and R3¿ have the meanings indicated in the claims, which are valuable pharmaceutical active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular disorders such as high blood pressure, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of formula (I) have the ability to modulate the endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of disease states which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for the preparation of compounds of formula (I), their use for the therapy and prophylaxis of the designated disease states and for the production of pharmaceuticals therefor, and pharmaceutical compositions which comprise a compound of formula (I).
-
10.发明公开SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM 有权硫取代sulfonylaminocarboxylic酸N-芳基酰胺，生产，其使用含有该药物组合物
公开(公告)号：EP1095016A1
公开(公告)日：2001-05-02
申请号：EP99929318.6
申请日：1999-06-25
IPC分类号： C07C311/46 , C07C323/41 , C07C323/42 , C07C317/40 , C07D295/22 , C07D211/96 , C07D333/34 , C07D277/46 , C07D235/28 , C07D261/16 , A61K31/18 , A61K31/38 , A61K31/42 , A61K31/44
CPC分类号： C07C311/21 , C07C311/46 , C07C311/51 , C07C311/58 , C07C317/40 , C07C323/42 , C07C323/52 , C07C323/60 , C07C331/12 , C07C2601/02 , C07C2601/14 , C07C2602/04 , C07C2602/08 , C07D207/12 , C07D207/16 , C07D207/20 , C07D207/48 , C07D209/10 , C07D209/14 , C07D211/46 , C07D211/54 , C07D211/62 , C07D211/96 , C07D213/71 , C07D213/78 , C07D213/80 , C07D213/82 , C07D215/36 , C07D221/20 , C07D231/18 , C07D231/38 , C07D231/42 , C07D233/84 , C07D235/18 , C07D239/06 , C07D239/26 , C07D239/42 , C07D243/08 , C07D261/10 , C07D261/16 , C07D265/30 , C07D277/04 , C07D277/36 , C07D277/46 , C07D277/52 , C07D277/54 , C07D277/64 , C07D279/12 , C07D295/26 , C07D333/34 , C07D333/38 , C07D333/40 , C07D401/12 , C07D413/12 , C07D491/10
摘要： The present invention relates to compounds of formula (I), wherein A?1, A2, R1, R2, R3¿, X and n are as defined in the claims, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of formula (I) are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of formula (I), to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of formula (I).
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.021 秒)
